GlassScriptPhysician profile
John Sotiriadis
NPI 1659578664
$36,910.42
in general payments reported to CMS, 2019-2025
21 companies · $864 in 2025
The $864 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $2,027 · 2021: $6,124 · 2022: $4,857 · 2023: $4,997 · 2024: $497 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Food and Beverage: $1,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Food and Beverage | $1,858.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $18,344.60 | 2019-2020 | |
| Abbvie INC. | $8,240.65 | 2020-2025 | Linzess, Viberzi, Mavyret |
| Ironwood Pharmaceuticals, INC | $6,957.41 | 2019-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,238.52 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $317.43 | 2022-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $294.93 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $226.92 | 2019-2025 | Simponi Aria, Simponi, Stelara |
| Redhill Biopharma INC. | $197.55 | 2020-2025 | Talicia |
| Cumberland Pharmaceuticals, INC. | $190.82 | 2019-2020 | |
| Pfizer INC. | $158.63 | 2019-2025 | |
| Gilead Sciences, INC. | $154.09 | 2019-2025 | |
| Braintree Laboratories, INC. | $118.61 | 2019-2025 | Suflave |
| Ferring Pharmaceuticals INC. | $104.84 | 2019-2025 | Rebyota |
| Celgene Corporation | $74.64 | 2021-2023 | Zeposia |
| Celltrion USA INC. | $69.53 | 2025 | Vegzelma |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $54.89 | 2020-2021 | |
| Novo Nordisk INC | $41.07 | 2025 | Wegovy |
| Boston Scientific Corporation | $38.15 | 2019 | |
| Phathom Pharmaceuticals, INC. | $34.65 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $29.16 | 2020-2021 | |
| Genzyme Corporation | $23.33 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sotiriadis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.